Mohyeldin Moiud, Abuelgasim Ahmed S, Mustafa Ahmed Mg
Department of Internal Medicine, University of Medical Sciences and Technology, Khartoum 11111, Sudan.
World J Cardiol. 2024 Jul 26;16(7):397-401. doi: 10.4330/wjc.v16.i7.397.
Peripheral artery disease (PAD) is a common condition characterized by atherosclerosis in the peripheral arteries, associated with concomitant coronary and cerebrovascular diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a class of drugs that have shown potential in hypercholesterolemic patients. This review focuses on the efficacy, safety, and clinical outcomes of PCSK9 inhibitors in PAD based on the literature indexed by PubMed. Trials such as FOURIER and ODYSSEY demonstrate the efficacy of evolocumab and alirocumab in reducing cardiovascular events, offering a potential treatment option for PAD patients. Safety evaluations from trials show few adverse events, most of which are injection-site reactions, indicating the overall safety profile of PCSK9 inhibitors. Clinical outcomes show a reduction in cardiovascular events, ischemic strokes, and major adverse limb events. However, despite these positive findings, PCSK9 inhibitors are still underutilized in clinical practice, possibly due to a lack of awareness among care providers and cost concerns. Further research is needed to establish the long-term effects and cost-effectiveness of PCSK9 inhibitors in PAD patients.
外周动脉疾病（PAD）是一种常见病症，其特征为外周动脉粥样硬化，并伴有冠状动脉疾病和脑血管疾病。前蛋白转化酶枯草溶菌素9型（PCSK9）抑制剂是一类已在高胆固醇血症患者中显示出潜力的药物。本综述基于PubMed索引的文献，聚焦于PCSK9抑制剂在PAD中的疗效、安全性和临床结局。FOURIER和ODYSSEY等试验证明了依洛尤单抗和阿利西尤单抗在减少心血管事件方面的疗效，为PAD患者提供了一种潜在的治疗选择。试验的安全性评估显示不良事件较少，其中大多数是注射部位反应，表明PCSK9抑制剂的总体安全性。临床结局显示心血管事件、缺血性中风和主要肢体不良事件有所减少。然而，尽管有这些积极的发现，但PCSK9抑制剂在临床实践中的使用仍然不足，这可能是由于医护人员缺乏认识以及成本问题。需要进一步研究以确定PCSK9抑制剂在PAD患者中的长期影响和成本效益。
